case_images: PMC11807954_01
case_images: A flowchart showing the selection process for the 10 selected studies.
case_images: fonc-14-1521253-g001.jpg
case_images: PMC11807954_01_fonc-14-1521253-g001.jpg
case_images: f1
case_images: Ultrasound revealed a solid mass measuring 10.9 cm x 9.3 cm x 9.3 cm on the left side of the uterus ( Supplementary Figure S1A ). Pelvic magnetic resonance imaging (MRI) later showed a solid mass in the left pelvis, measuring 10.5 cm x 8.2 cm x 9.5 cm with uneven enhancement ( Supplementary Figures S1B, C ). The selection flowchart is presented in  Figure 1 .
case_images: The survival curve of patients in subgroups by immunohistochemistry (A) and treatment (B).
case_images: fonc-14-1521253-g002.jpg
case_images: PMC11807954_01_fonc-14-1521253-g002.jpg
case_images: f2
case_images: No mitotic figures, vascular invasion, haemorrhage, or necrosis were observed ( Supplementary Figure S2A ). The immunohistochemical results were as follows: positive staining for SMA ( Supplementary Figure S2B ), desmin ( Supplementary Figure S2C ), melan A ( Supplementary Figure S2D ), Ki-67 (20%), and TFE3 ( Supplementary Figure S2E ). In addition, fluorescence in situ hybridisation (FISH) did not detect TFE3 gene rearrangement ( Supplementary Figure S2F ). Patients with group A tumours demonstrated longer disease-free survival compared to those with group B tumours ( Figure 2A ). Disease-free survival did not differ significantly between patients who underwent hysterectomy and those who underwent mass resection for uterine PEComas of uncertain malignant potential ( Table 2 ,  Figure 2B ).